What Analyst Projections for Key Metrics Reveal About Boston Scientific (BSX) Q4 Earnings

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.65 per share, indicating an increase of 18.2% compared to the year-ago period. Analysts forecast revenues of $4.4 billion, representing an increase of 18.1% year over year.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.Given this perspective, it's time to examine the average forecasts of specific Boston Scientific metrics that are routinely monitored and predicted by Wall Street analysts.According to the collective judgment of analysts, 'Net Sales- MedSurg- Worldwide' should come in at $1.56 billion. The estimate suggests a change of +8.1% year over year.The average prediction of analysts places 'Net Sales- Cardiovascular- Worldwide' at $2.84 billion. The estimate indicates a change of +24.3% from the prior-year quarter.Analysts expect 'Net Sales- Cardiovascular- Cardiology- Worldwide' to come in at $2.22 billion. The estimate indicates a year-over-year change of +26.6%.The combined assessment of analysts suggests that 'Net Sales- Cardiovascular- Peripheral Interventions- Worldwide' will likely reach $628.06 million. The estimate suggests a change of +17.8% year over year.It is projected by analysts that the 'Geographic Revenue- Rest of the World' will reach $1.70 billion. The estimate suggests a change of +12.4% year over year.The collective assessment of analysts points to an estimated 'Geographic Revenue- U.S.' of $2.72 billion. The estimate indicates a change of +23% from the prior-year quarter.Analysts forecast 'Net Sales- Cardiovascular- Peripheral Interventions- International' to reach $278.07 million. The estimate suggests a change of +14.9% year over year.Analysts' assessment points toward 'Net Sales- MedSurg- Neuromodulation- United States' reaching $234.32 million. The estimate indicates a year-over-year change of +13.8%.The consensus estimate for 'Net Sales- MedSurg- Neuromodulation- International' stands at $66.10 million. The estimate indicates a year-over-year change of +4.9%.The consensus among analysts is that 'Net Sales- MedSurg- Endoscopy- United States' will reach $422.39 million. The estimate suggests a change of +7.2% year over year.Analysts predict that the 'Net Sales- MedSurg- Endoscopy- International' will reach $269.52 million. The estimate indicates a change of +7% from the prior-year quarter.Based on the collective assessment of analysts, 'Net Sales- MedSurg- Urology- United States' should arrive at $417.17 million. The estimate points to a change of +15.2% from the year-ago quarter.View all Key Company Metrics for Boston Scientific here>>>Shares of Boston Scientific have experienced a change of +15.3% in the past month compared to the +2.9% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), BSX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks